3,459 Shares in Repligen Corporation $RGEN Acquired by United Services Automobile Association

Key Points

• United Services Automobile Association has acquired 3,459 shares of Repligen Corporation valued at approximately $461,000 during the first quarter of this year.
• Repligen reported quarterly earnings of $0.37 per share, missing the consensus estimate of $0.40, while revenue increased by 14.8% year-over-year to $182.37 million.
• Several analysts have issued ratings for Repligen, with target prices ranging from $130.00 to $205.00, reflecting a consensus rating of "Moderate Buy."

United Services Automobile Association bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,459 shares of the biotechnology company's stock, valued at approximately $461,000.

Other hedge funds have also recently bought and sold shares of the company. Alliance Wealth Advisors LLC UT increased its position in shares of Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 89 shares in the last quarter. State of Michigan Retirement System raised its position in Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after purchasing an additional 100 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after buying an additional 100 shares during the period. State of Wyoming grew its stake in shares of Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock valued at $297,000 after buying an additional 115 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after buying an additional 128 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RGEN shares. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price target for the company in a report on Tuesday, July 22nd. Wells Fargo & Company decreased their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Jefferies Financial Group cut their price objective on shares of Repligen from $145.00 to $135.00 and set a "hold" rating on the stock in a report on Friday. Evercore ISI decreased their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Price Performance

Shares of Repligen stock traded up $2.69 on Tuesday, hitting $116.43. The company had a trading volume of 397,303 shares, compared to its average volume of 771,028. The business has a 50-day simple moving average of $120.52 and a 200-day simple moving average of $127.26. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a market cap of $6.55 billion, a PE ratio of -464.57, a PEG ratio of 2.09 and a beta of 1.07. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.